Brief: Cingulate Presents Full Trial Results From Phase 3 Adult Efficacy And Safety Trial Of CTX-1301 For ADHD At Psych Congress 2023
05/09/2023 14:08
Sept 5 (Reuters) - Cingulate Inc CING.O :
* CINGULATE ANNOUNCES PRESENTATION OF FULL TRIAL RESULTS
FROM
PHASE 3 ADULT EFFICACY AND SAFETY TRIAL OF CTX-1301
(DEXMETHYLPHENIDATE) FOR ADHD AT PSYCH CONGRESS 2023
Source text for Eikon: ID:nGNX6sBQg8
Further company coverage: CING.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)